Rational discovery of novel nuclear hormone receptor antagonists

被引:96
作者
Schapira, M
Raaka, BM
Samuels, HH
Abagyan, R
机构
[1] NYU, Sch Med, Skirball Inst Biomol Med, New York, NY 10016 USA
[2] NYU, Sch Med, Div Mol Endocrinol, Dept Med, New York, NY 10016 USA
[3] NYU, Sch Med, Div Mol Endocrinol, Dept Pharmacol, New York, NY 10016 USA
关键词
D O I
10.1073/pnas.97.3.1008
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Nuclear hormone receptors (NRs) are potential targets for therapeutic approaches to many clinical conditions, including cancer, diabetes, and neurological diseases. The crystal structure of the ligand binding domain of agonist-bound NRs enables the design of compounds with agonist activity. However, with the exception of the human estrogen receptor-alpha, the lack of antagonist-bound "inactive" receptor structures hinders the rational design of receptor antagonists. In this study, we present a strategy for designing such antagonists. We constructed a model of the inactive conformation of human retinoic acid receptor-alpha by using information derived from antagonist-bound estrogen receptor-alpha and applied a computer-based virtual screening algorithm to identify retinoic acid receptor antagonists. Thus, the currently available crystal structures of NRs may be used for the rational design of antagonists, which could lead to the development of novel drugs for a variety of diseases.
引用
收藏
页码:1008 / 1013
页数:6
相关论文
共 36 条
[21]   CRYSTAL-STRUCTURE OF THE RAR-GAMMA LIGAND-BINDING DOMAIN BOUND TO ALL-TRANS-RETINOIC ACID [J].
RENAUD, JP ;
ROCHEL, N ;
RUFF, M ;
VIVAT, V ;
CHAMBON, P ;
GRONEMEYER, H ;
MORAS, D .
NATURE, 1995, 378 (6558) :681-689
[22]   The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen [J].
Shiau, AK ;
Barstad, D ;
Loria, PM ;
Cheng, L ;
Kushner, PJ ;
Agard, DA ;
Greene, GL .
CELL, 1998, 95 (07) :927-937
[23]   Effects of novel RAR- and RXR-selective retinoids on myeloid leukemic proliferation and differentiation in vitro [J].
Shiohara, M ;
Dawson, MI ;
Hobbs, PD ;
Sawai, N ;
Higuchi, T ;
Koike, K ;
Komiyama, A ;
Koeffler, HP .
BLOOD, 1999, 93 (06) :2057-2066
[24]   PPAR-γ:: Adipogenic regulator and thiazolidinedione receptor [J].
Spiegelman, BM .
DIABETES, 1998, 47 (04) :507-514
[25]   Molecular docking programs successfully predict the binding of a beta-lactamase inhibitory protein to TEM-1 beta-lactamase [J].
Strynadka, NCJ ;
Eisenstein, M ;
KatchalskiKatzir, E ;
Shoichet, BK ;
Kuntz, ID ;
Abagyan, R ;
Totrov, M ;
Janin, J ;
Cherfils, J ;
Zimmerman, F ;
Olson, A ;
Duncan, B ;
Rao, M ;
Jackson, R ;
Sternberg, M ;
James, MNG .
NATURE STRUCTURAL BIOLOGY, 1996, 3 (03) :233-239
[26]  
Sun SY, 1997, CANCER RES, V57, P4931
[27]   Identification of a retinoic acid receptor alpha subtype specific agonist [J].
Teng, M ;
Duong, TT ;
Klein, ES ;
Pino, ME ;
Chandraratna, RAS .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (16) :3035-3038
[28]  
Toma S, 1998, INT J CANCER, V78, P86, DOI 10.1002/(SICI)1097-0215(19980925)78:1<86::AID-IJC14>3.0.CO
[29]  
2-3
[30]   DETAILED AB-INITIO PREDICTION OF LYSOZYME-ANTIBODY COMPLEX WITH 1.6-ANGSTROM ACCURACY [J].
TOTROV, M ;
ABAGYAN, R .
NATURE STRUCTURAL BIOLOGY, 1994, 1 (04) :259-263